reports
OPKO Health to Participate in the Jefferies Biotech on the Beach Summi...
OPKO Health to Participate in the Jefferies Biotech on the Beach Summit MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will be holding one-on-one meetings with investors registered for the event on Wednesday, March 11th. Investors interested in scheduling a meeting with OPKO management should contact their Jefferies representative. About OPKO Health OPKO is a multinational biopharmaceutic...
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financ...
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This n...
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Result...
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s website ...
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
POOL POOL CORPORATION
NEU NEWMARKET CORPORATION
LXRX LEXICON PHARMACEUTICALS INC.
HUM HUMANA INC.
HTGC HERCULES CAPITAL INC.
AMH AMERICAN HOMES 4 RENT CLASS A
GGT THE GABELLI MULTIMEDIA TRUST
HLNE HAMILTON LANE INCORPORATED CLASS A
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
SONO SONOS
VERX VERTEX
WRB INC.
W.R. BERKLEY CORPORATION
- Jonathan Moreland
PCTY PAYLOCITY HOLDING CORP.
LXRX LEXICON PHARMACEUTICALS INC.
FFIN FIRST FINANCIAL BANKSHARES INC
ARDX ARDELYX INC
CNDT CONDUENT INC.
A2JHXF CEVA LOGISTICS AG
AVTR AVANTOR
VERX INC.
CVRX VERTEX
ELF INC.
NPWR CVRX
TLSI INC.
PMN E.L.F. BEAUTY
GF INC.
HYMC NET POWER INC
FIG TRISALUS LIFE SCIENCES INC
PROMIS NEUROSCIENCES INC.
THE NEW GERMANY FUND
INC.
HYCROFT MINING HOLDING CORPORATION
FIGMA INC.
- Jonathan Moreland
PCTY PAYLOCITY HOLDING CORP.
LXRX LEXICON PHARMACEUTICALS INC.
FAF FIRST AMERICAN FINANCIAL CORPORATION
MEDP MEDPACE HOLDINGS INC.
PRU PRUDENTIAL PLC
SAH SONIC AUTOMOTIVE INC. CLASS A
MSFT MICROSOFT CORPORATION
SSTI SHOTSPOTTER
KKR KKR & CO. INC.
DKNG DRAFTKINGS INC
VERX VERTEX
DLHC INC.
FLYW DALEIGH HOLDINGS CORP
WRB FLYWIRE CORP
IE W.R. BERKLEY CORPORATION
NPWR IVANHOE ELECTRIC INC
GDV NET POWER INC
THE GABELLI DIVIDEND & INCOME TRUST
Lexicon Pharmaceuticals Inc: 1 director
A director at Lexicon Pharmaceuticals Inc bought 268,497 shares at 1.314USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
OPKO Health to Report Fourth Quarter 2025 Financial Results on Februar...
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-r...
- Jonathan Moreland
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
TCBI TEXAS CAPITAL BANCSHARES INC.
SXI STANDEX INTERNATIONAL CORPORATION
PAYX PAYCHEX INC.
NBTB NBT BANCORP INC.
MNRO MONRO INC
LXRX LEXICON PHARMACEUTICALS INC.
LMAT LEMAITRE VASCULAR INC.
HUN HUNTSMAN CORPORATION
GME GAMESTOP CORP. CLASS A
FFIN FIRST FINANCIAL BANKSHARES INC
CR CRANE CO.
GAM GENERAL AMERICAN INVESTORS CO. INC.
ENPH ENPHASE ENERGY INC.
PCF PUTNAM HIGH INCOME SECURITIES FUND
AGYS AGILYSYS INC.
TYIA JOHNSON CONTROLS INTERNATIONAL PLC
LW LAMB WESTON HOLDINGS INC.
HWKN HAWKINS INC.
WDFC WD-40 COMPANY
HYT BLACKROCK CORPORATE HIGH YIELD FUND VI
CVCO CAVCO INDUSTRIES INC.
CRVS CORVUS PHARMACEUTICALS
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
ABT ABBOTT LABORATORIES
MVBF MVB FINANCIAL CORP
THM INTERNATIONAL TOWER HILL MINES LTD
NWFL NORWOOD FINANCIAL CORP.
ZIVO ZIVO BIOSCIENCE
SONO INC.
ANIX SONOS
ETON ANIXA BIOSCIENCES
AMTB ETON PHARMACEUTICALS
JYNT AMERANT BANCORP (A)
ALLY THE JOINT
CMTV GMAC LLC
ALXO COMMUNITY BANCORP INC. VT
AZYO ALX ONCOLOGY HOLDINGS
LUMN AZIYO BIOLOGICS
BST LUMEN TECHNOLOGIES INC.
LSF BLACKROCK SCIENCE AND TECHNOLOGY TRUST
VANI LAIRD SUPERFOOD INC
BOF VIVANI MEDICAL INC
WS WI BRANCHOUT FOOD INC.
MXF WORTHINGTON STEEL
GDV THE MEXICO FUND
PMN INC.
IP THE GABELLI DIVIDEND & INCOME TRUST
CVM PROMIS NEUROSCIENCES INC.
FEAM INTER PHARMA PUBLIC COMPANY LIMITED
BDSX CEL-SCI CORPORATION
MIGI 5E ADVANCED MATERIALS INC.
BIODESIX INC
MAWSON INFRASTRUCTURE GROUP INC
Lexicon Announces Closing of Approximately $94.6 Million Public Offeri...
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the closing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001, and concurrent private placement of 22,400,000 shares of common stock and 367,145 shares of series b convertible preferred stock (the “Series B Convertible Preferred Stock”). The shares of common stock offered pursuant to the publi...
- Jonathan Moreland
SXI STANDEX INTERNATIONAL CORPORATION
LXRX LEXICON PHARMACEUTICALS INC.
FFIN FIRST FINANCIAL BANKSHARES INC
PCF PUTNAM HIGH INCOME SECURITIES FUND
CVCO CAVCO INDUSTRIES INC.
RRBI RED RIVER BANCSHARES
ALXO ALX ONCOLOGY HOLDINGS
FRST PRIMIS FINANCIAL CORP
WRB W.R. BERKLEY CORPORATION
GAM GENERAL DE ALQUILER DE MAQUINARIA
FIG FIGMA INC.
FEAM 5E ADVANCED MATERIALS INC.
Citizens Business Bank Recognized by Forbes as a Best Bank in America ...
Citizens Business Bank Recognized by Forbes as a Best Bank in America for 2026 ONTARIO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CVB Financial Corp. (NASDAQ: CVBF), the holding company for Citizens Business Bank, N.A. (the “Bank”), has been recognized by Forbes in the publication’s seventeenth annual America’s Best Banks list. This recognition represents the ninth time in the past decade that the Bank has been included on Forbes’ list of the best banks in the nation. “We are grateful to be recognized once again for our strong financial performance,” said David Brager, President and Chie...
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Clas...
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; o...
Lexicon Announces Pricing of Approximately $94.6 Million Public Offeri...
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $1.30 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering a...
Lexicon Announces Proposed Public Offering of Common Stock
Lexicon Announces Proposed Public Offering of Common Stock THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the p...
- David Barden
The future of US wireless, right now - Extrapolating 3Q25 wireless tre...
We are taking 3Q25 results and the most recent cNPS data and laying out our latest thinking and forecasts ahead of 4Q results. We expect 4Q results and attendant 2026 guidance to contain material information value for investors and we wanted to share our latest forecasts, data, and trends as a starting point as we navigate this impactful season.
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27,...
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, 2026. The event will commemorate Lexicon’s 30th anniversary as a biopharmaceutical company building a differentiated pipeline of oral small-molecule therapies for people living with serious cardiometabolic diseases and chronic neuropathic pain. “In its early days, Lexicon was focused on pioneering a deeper understa...
CVB Financial Corp. Reports Earnings for the Fourth Quarter and the Ye...
CVB Financial Corp. Reports Earnings for the Fourth Quarter and the Year Ended 2025 Fourth Quarter 2025 Net Earnings of $55.0 million, or $0.40 per share Return on Average Assets of 1.40%Net Interest Margin of 3.49% Full Year 2025 Net Earnings of $209.3 million, or $1.52 per shareReturn on Average Assets of 1.36% Return on Average Tangible Common Equity of 14.28% Ontario, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- CVB Financial Corp. (NASDAQ:CVBF) and its subsidiary, Citizens Business Bank, National Association (the “Company”), announced earnings for the quarter and the year ended Decemb...
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting wi...
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain – No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo – THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) for pilavapadin in diabetic peripheral neuropathic pain (DPNP). During the ...
- Blair Levin
DISH Antitrust Challenge to DIS; Will Content or Distribution Gain Fle...
Earlier this month DISH filed an antitrust complaint against DIS in the latest chapter of a long running dispute over DIS’s efforts to create new sports bundles and DISH’s efforts to create new options for how its customers access programming over its platform. In this note we explore the implications of the battle, how it might affect the flexibility of content and distribution in seeking to adjust to thrive in the media world to come, and what it could tell us about the direction of media and...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.